Watch OVID. Know when insiders buy.
One email the day a filing lands. Free.
OVID
Ovid Therapeutics Inc.
2.49
−0.08 −2.92%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
62
WATCH · shorts 62
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $487.3MP/E —DIV YIELD —FCF YIELD —REV TTM $1.6M −76.2%NET INCOME −$34.5MNET CASH —52W 1.20 – 2.96SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $733K | −88.3% | — | −$15.7M | −$15M | — | — | −$17.6M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$17.8M | −$17M | — | — | −$13.9M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | $718K | +844.7% | — | −$12.3M | $9.7M | — | — | −$10.4M | $0 | −$10.4M | Mar 18 |
| Q3 2025 · Sep 30 | $132K | −23.7% | — | −$12.5M | −$12.2M | — | — | −$12.9M | $0 | −$12.9M | Nov 12 |
| Q2 2025 · Jun 30 | $6.3M | +3611.2% | — | −$5.1M | −$4.7M | −155.0% | — | −$4.8M | $0 | −$4.8M | Aug 13 |
| Q1 2025 · Mar 31 | $130K | −12.2% | — | −$12.6M | −$10.2M | — | — | −$10.3M | $0 | −$10.3M | Aug 13 |
| Q4 2024 · Dec 31derived | $76K | −46.5% | — | −$10.7M | −$9.3M | — | — | −$10M | $22K | −$10M | Mar 18 |
| Q3 2024 · Sep 30 | $173K | +58.7% | — | −$13.2M | −$14M | — | -0.20 | −$15M | −$4K | −$15M | Nov 12 |
| Q2 2024 · Jun 30 | $169K | — | — | −$20.5M | $8.5M | — | 0.12 | −$14.3M | $34K | −$14.3M | Nov 12 |
| Q1 2024 · Mar 31 | $148K | — | — | −$17.4M | −$11.7M | — | -0.17 | −$16.7M | $19K | −$16.7M | Nov 12 |
| Q4 2023 · Dec 31derived | $142K | — | — | −$18.2M | −$15.3M | — | -0.22 | −$11.9M | $13K | −$11.9M | Mar 11 |
| Q3 2023 · Sep 30 | $109K | — | — | −$12M | −$11.3M | — | -0.16 | −$10.1M | $6K | −$10.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.3M | — | −$42.4M | −$17.4M | -240.1% | — | −$38.3M | $0 | −$38.3M | — | — |
| FY2024 · to Dec 31 | $566K | — | −$61.9M | −$26.4M | -4670.1% | — | −$56M | $71K | −$56M | — | — |
| FY2023 · to Dec 31 | $392K | — | −$59.3M | −$52.3M | -13351.8% | -0.74 | −$45.8M | $40K | −$45.8M | — | — |
| FY2022 · to Dec 31 | $1.5M | — | −$55.5M | −$54.2M | -3604.7% | -0.77 | −$55.2M | $1.2M | −$56.5M | — | — |
| FY2021 · to Dec 31 | $208.4M | — | $124.2M | $122.8M | 58.9% | 1.76 | $118.6M | $184K | $118.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$81.4M | −$81M | — | -1.39 | −$51.6M | $127K | −$51.7M | — | — |
Every number comes from Ovid Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.